

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Lisdexamfetamine dimesilate

INITIATION

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a paediatrician or psychiatrist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- Patient is currently on treatment with lisdexamfetamine dimesilate and met all remaining criteria prior to commencing treatment

or

- ADHD (Attention Deficit and Hyperactivity Disorder)

and

- Diagnosed according to DSM-V or ICD 11 criteria

and

- Patient is taking a currently subsidised formulation of atomoxetine or methylphenidate hydrochloride (extended-release) and has not received sufficient benefit or has experienced intolerable side effects

or

- Patient is taking a currently subsidised formulation of dexamfetamine sulfate (immediate-release) which has not been effective due to significant administration and/or treatment adherence difficulties

or

- There is significant concern regarding the risk of diversion or abuse of immediate release dexamfetamine sulfate

or

- Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained release) which has not been effective due to significant administration and/or treatment adherence difficulties

or

- There is significant concern regarding the risk of diversion or abuse of immediate release methylphenidate hydrochloride

or

- Patient would have been prescribed a subsidised formulation of methylphenidate hydrochloride (extended-release) but has been unable to access due to supply issues with methylphenidate hydrochloride (extended-release)

and

- Other alternative stimulant presentations (methylphenidate or dexamfetamine) are not appropriate

and

- Lisdexamfetamine dimesilate is not to be used in combination with another funded methylphenidate presentation

I confirm that the above details are correct:

Signed: Date: